IPP Bureau
Lilly partners with API to launch ‘Obesity Gurukul’ in India
By IPP Bureau - July 15, 2025
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization
By IPP Bureau - July 15, 2025
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
WHO, ITU, and WIPO release new report on AI use in traditional medicine
By IPP Bureau - July 15, 2025
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly
By IPP Bureau - July 15, 2025
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
By IPP Bureau - July 15, 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Zydus receives final approval from USFDA for Celecoxib Capsules
By IPP Bureau - July 15, 2025
Celecoxib is a nonsteroidal anti-inflammatory drug
Cupid invests in GII Healthcare Investment
By IPP Bureau - July 15, 2025
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
Merck launches AAW workstation to advance lab automation
By IPP Bureau - July 15, 2025
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Sun Pharma launches LEQSELVI in US for treatment of severe alopecia areata
By IPP Bureau - July 14, 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
By IPP Bureau - July 14, 2025
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Sun Pharma settles patent litigation with Incyte
By IPP Bureau - July 14, 2025
Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
By IPP Bureau - July 14, 2025
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
By IPP Bureau - July 14, 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’
By IPP Bureau - July 13, 2025
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Evonik opens new medical device center in Shanghai
By IPP Bureau - July 12, 2025
The company’s largest center for medical device applications, serving the entire Asian market
